TP receptor activation and inhibition in atherothrombosis: The paradigm of diabetes mellitus

Internal and Emergency Medicine

Volumn 6, Issue 3, 2011, Pages 203-212

  Santilli, Francesca ^a   Mucci, Luciana ^b   Davì, Giovanni ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Aspirin; Atherothrombosis; Diabetes mellitus; Oxidative stress; TP antagonism

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; THROMBOXANE RECEPTOR;

ATHEROSCLEROTIC PLAQUE; DIABETES MELLITUS; DRUG ANTAGONISM; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; REVIEW; THROMBOSIS;

ASPIRIN; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; PLAQUE, ATHEROSCLEROTIC; PLATELET AGGREGATION INHIBITORS; RECEPTORS, THROMBOXANE; THROMBOSIS;

EID: 79956302853     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-010-0440-3     Document Type: Review

References (50)

1. Schramm TK, Gislason GH, Kober L et al (2008) Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3. 3 million people. Circulation 117: 1945-1954.
2. Ferroni P, Basili S, Falco A, Davì G (2004) Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2: 1282-1291.
3. Davì G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C (1990) Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322: 1769-1774.
4. Watala C, Boncler M, Gresner P (2005) Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep 57(Suppl): S42-58.
5. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105: 1650-1655.
6. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373: 1849-1860.
7. 2 receptor from human blood platelets. J Biol Chem 264: 16496-16501.
8. Davì G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357: 2482-2494.
9. Patrono C, García Rodríguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353: 2373-2383.
10. 2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 118: 18-35.
11. 2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 114: 784-794.
12. 2 modulates migration, proliferation, and differentiation of adipose tissue-derived mesenchymal stem cells. Exp Mol Med 41: 17-24.
13. 2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59: 4574-4577.
14. 2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 96: 2280-2286.
15. Mehta P, Mehta J, Lawson D, Krop I, Letts LG (1986) Leukotrienes potentiate the effects of epinephrine and thrombin on human platelet aggregation. Thromb Res 41: 731-738.
16. 2 for their receptor are similar in washed human platelets. Biochem Biophys Res Commun 157: 733-739.
17. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD (2001) Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41: 661-690.
18. Habib A, FitzGerald GA, Maclouf J (1999) Phosphorylation of the thromboxane receptor α, the predominant isoform expressed in human platelets. J Biol Chem 274: 2645-2651.
19. 2 receptor isoforms in human platelets. Opposite coupling to adenylcyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest 97: 949-956.
20. 2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation 112: 3001-3008.
21. Gaussem P, Reny JL, Thalamas C et al (2005) The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. J Thromb Haemost 3: 1437-1445.
22. Chamorro A (2009) TP receptor antagonism: a new concept in atherothrombosis and stroke prevention. Cerebrovasc Dis 27(Suppl): 20-27.
23. Egan KM, Wang M, Lucitt MB et al (2005) Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111: 334-342.
24. 2. Science 296: 539-541.
25. Zou MH, Shi C, Cohen RA (2002) High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H2 receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes 51: 198-203.
26. 2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 25: 1845-1852.
27. Violi F, Hiatt W (2007) A critical review of antiplatelet treatment in peripheral arterial disease. Intern Emerg Med 2: 84-87.
28. Davì G, Gresele P, Violi F et al (1997) Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 96: 69-75.
29. Gresele P, Guglielmini G, De Angelis M et al (2003) Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 41: 1013-1020.
30. The DECODE Study Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354: 617-621.
31. Patrono C, Falco A, Davì G (2005) Isoprostane formation and inhibition in atherothrombosis. Curr Opin Pharmacol 5: 198-203.
32. Davì G, Falco A (2005) Oxidant stress, inflammation and atherogenesis. Lupus 14: 760-764.
33. Davì G, Ciabattoni G, Consoli A et al (1999) In vivo formation of 8-iso-prostaglandinF2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99: 224-229.
34. Vazzana N, Santilli F, Cuccurullo C, Davì G (2009) Soluble forms of RAGE in internal medicine. Intern Emerg Med 4: 389-401.
35. Devangelio E, Santilli F, Formoso G et al (2007) Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 43: 511-518.
36. Santilli F, Davì G, Consoli A et al (2006) Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 47: 391-397.
37. Di Minno G, Silver MJ, Cerbone AM, Murphy S (1986) Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 68: 886-891.
38. FitzGerald GA, Patrono C (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345: 433-442.
39. Watala C, Pluta J, Golanski J et al (2005) Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 83: 148-158.
40. American Diabetes Association (2010) Standards of medical care in diabetes. Diabetes Care 33(Suppl): S11-61.
41. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86.
42. Haynes R, Bowman L, Armitage J (2009) Aspirin for primary prevention of vascular disease in people with diabetes. BMJ 339: 1210-1211.
43. Rocca B, Patrono C (2005) Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 3: 1597-1602.
44. Angiolillo DJ, Bernardo E, Ramírez C et al (2006) Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. Am J Cardiol 97: 38-43.
45. Singla A, Antonino MJ, Bliden KP, Tantry US, Gurbel PA (2009) The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J 158: 784. e1-784. e6.
46. Di Chiara J, Bliden KP, Tantry US et al (2007) The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 56: 3014-3019.
47. Santilli F, Rocca B, De Cristofaro R et al (2009) Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol 53: 667-677.
48. Giustina A, Perini P, Desenzani P et al (1998) Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes 47: 423-430.
49. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici M, Mattle HP, Rothwell PM, PERFORM Study Investigators (2009) Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovasc Dis 27: 509-518.
50. Guthikonda S, Lev EI, Patel R et al (2007) Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 5: 490-496.